ABSTRACT

The present disclosure relates to antisense oligonucleotides, which target *SNCA* mRNA (*e.g.*, at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, *e.g.*, a neurological disorder.

No Figure